Clindamycin Phosphate IP 1.007%w/w + Adapalene BP 0.1% w/w*Preservative : Sodium Methylpargben IP 0.1%w/w + Phenoxyehenol IP 0.25%w/w Gel

Clindamycin Phosphate IP 1.007%w/w + Adapalene BP 0.1% w/w*Preservative : Sodium Methylpargben IP 0.1%w/w + Phenoxyehenol IP 0.25%w/w Gel is a gel formulated with Clindamycin Phosphate IP 1.007%w/w + Adapalene BP 0.1% w/w*Preservative : Sodium Methylpargben IP 0.1%w/w + Phenoxyehenol IP 0.25%w/w. The listed active ingredient profile is Clindamycin Phosphate w/w; Adapalene % w/w*Preservative : Sodium Methylpargben w/w; Phenoxyehenol w/w, placing the product in the topical antibacterial / dermatology category. The formulation contains topical antibacterial ingredient(s) intended for susceptible localized bacterial skin conditions. The dosage form is intended for topical/local application; the exact application site and frequency must follow the approved product instructions. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.